Get started
Author

Satoshi Konagai

Observed name: S. Konagai
Observed institution: Astellas Pharma (Japan)
OpenAlex ID: A5033175342
The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2014 · Masamichi Mori, Yoko Ueno, et al. · Molecular Cancer Therapeutics · 58
Abstract 1728: ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations
2014 · Hideki Sakagami, Satoshi Konagai, et al. · Cancer Research · 21
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
2019 · Hiroaki Tanaka, Hideki Sakagami, et al. · Molecular Cancer Therapeutics · 17
Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models.
2011 · Sadao Kuromitsu, Masamichi Mori, et al. · Molecular Cancer Therapeutics · 16
Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor -
2011 · Sadao Kuromitsu, Masamichi Mori, et al. · Cancer Research · 14
Abstract 2586: ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models
2015 · Satoshi Konagai, Hideki Sakagami, et al. · Cancer Research · 9
Abstract 866: ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model
2012 · Masamichi Mori, Sadao Kuromitsu, et al. · Cancer Research · 8
Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy
2023 · Toshihide Nishibata, Nobuaki Amino, et al. · BioMed Research International · 5
PDF
Abstract 2678: First demonstration of in vivo PET imaging for ALK inhibitor using [11C]ASP3026, a novel brain-permeable type of ALK inhibitor.
2013 · Hiroshi Fushiki, Rika Saito, et al. · Cancer Research · 3
Abstract B188: Preclinical antitumor activity of ASP8273, a mutant-selective irreversible EGFR inhibitor in an AXL-overexpressing NSCLC model
2015 · Naoki Kaneko, Hiroaki Tanaka, et al. · Molecular Cancer Therapeutics · 1
Abstract 918: ASP3026, a selective ALK inhibitor, shows anti-tumor activity in a mouse model xenografted with NCI-H2228 intracranially.
2013 · Satoshi Konagai, Hiroshi Fushiki, et al. · Cancer Research · 1
ASP3026, a Selective ALK Inhibitor, Induces Tumor Regression against Crizotinib Resistant EML4-ALK-Dependent Tumor Models in Mice
2012 · S. Konagai, M. Mori, et al. · Annals of Oncology · 1
PDF
Data from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
Data from Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
2023 · Hiroaki Tanaka, Hideki Sakagami, et al.
Supplementary Figure Legends from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
Supplementary Table 1 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
Supplementary Figure 1 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
Supplementary Figure 3 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
Supplementary Figure 2 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
PDF
Supplementary Table 4 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
PDF
Supplementary Table 3 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
PDF
Supplementary Figure 4 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
PDF
Supplementary Table 2 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
Supplementary Tables S1-S3; Supplementary Figures S1-S3; and Supplementary Materials and Methods from Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
2023 · Hiroaki Tanaka, Hideki Sakagami, et al.
PDF
Supplementary Figure 2 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
2023 · Masamichi Mori, Yoko Ueno, et al.
Works count: 30
Citation count: 154
H-index: 7
I10-index: 5
Year
Topic
Type